Naylor A R
Department of Vascular Surgery, University of Leicester, Clinical Sciences Building, Leicester, UK.
J Cardiovasc Surg (Torino). 2013 Feb;54(1 Suppl 1):1-7.
In 2011, numerous guidelines were updated to advise on the optimal management of patients with asymptomatic carotid disease. Despite being based on interpretation of the same body of literature, there was actually little international consensus. Whilst we now know much more about what constitutes "state of the art" medical management, we still cannot identify the small proportion of "high risk for stroke" patients in whom to target carotid endarterectomy or carotid artery stenting. This is essential, as about 95% of patients undergoing either treatment strategy will ultimately undergo an unnecessary intervention. There is compelling evidence that the annual risk of stroke (on medical therapy) in patients with asymptomatic carotid disease has declined significantly. Guideline makers cannot continue to extrapolate rationales for justifying "mass interventions" in contemporary practice that are based on historical trial data. Accordingly, there is no consensus as to what should be considered "state of the art" management of asymptomatic carotid disease.
2011年,众多指南进行了更新,就无症状性颈动脉疾病患者的最佳管理提供建议。尽管这些指南都是基于对同一批文献的解读,但实际上国际上几乎没有达成共识。虽然我们现在对什么构成“最先进”的药物治疗了解得更多了,但我们仍然无法识别出一小部分适合进行颈动脉内膜切除术或颈动脉支架置入术的“中风高危”患者。这一点至关重要,因为接受这两种治疗策略的患者中约95%最终将接受不必要的干预。有令人信服的证据表明,无症状性颈动脉疾病患者(接受药物治疗时)的年度中风风险已显著下降。指南制定者不能继续基于历史试验数据推断在当代实践中为“大规模干预”辩护的理由。因此,对于无症状性颈动脉疾病的“最先进”管理应包括哪些内容,目前尚无共识。